These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17532718)

  • 41. Effective Immunochemotherapy For Aggressive Non-Hodgkin's Lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31 Suppl 2():7-11. PubMed ID: 28140109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index.
    Aydin F; Ulusoy S; Ovali E
    J Chemother; 1997 Dec; 9(6):446-51. PubMed ID: 9491847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?
    Truong LL; Scott L; Pal RS; Jalink M; Gunasekara S; Wijeratne DT
    Ecancermedicalscience; 2022; 16():1430. PubMed ID: 36158986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
    Pettit SD; Kirch R
    Cardiooncology; 2018; 4():5. PubMed ID: 32154005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of cardiotoxicity among survivors of childhood cancer.
    Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
    Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin's Lymphoma.
    Limat S; Demesmay K; Fagnoni P; Voillat L; Bernard Y; Deconinck E; Brion A; Arveux P; Cahn JY; Woronoff-Lemsi MC
    Clin Drug Investig; 2005; 25(11):719-29. PubMed ID: 17532718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
    Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
    J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
    J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study.
    Durand-Zaleski I; Bertrand M
    Pharmacoeconomics; 2004; 22 Suppl 4():19-27. PubMed ID: 15876009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
    Milpied N; Deconinck E; Gaillard F; Delwail V; Foussard C; Berthou C; Gressin R; Lucas V; Colombat P; Harousseau JL;
    N Engl J Med; 2004 Mar; 350(13):1287-95. PubMed ID: 15044639
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.